Coronary artery disease, including myocardial infarction (MI), is a leading cause of morbidity and mortality in the United States. Due to the limited self-renewal capacity of cardiac tissue, MIs can lead to progressive heart disease with a lasting impact on health and quality of life. The recent discovery of cardiac stem cells has incited research into their potential therapeutic applications for patients suffering from cardiovascular disease. Studies have demonstrated the ability of stem cells to both generate cardiac tissues in vitro and aid in the recovery of cardiovascular function in vivo in animal models. However, the long-term efficacy of stem cells as regenerative therapy is still unknown. Exploration of alternative therapies is underway, including the use of cardiac growth factor neuregulin-1 (NRG-1). Research has demonstrated that NRG-1 not only has direct effects on cardiomyocytes (CM) but also acts within the tissues supporting the CM. Transplantation of NRG-1 into ischemic cardiac tissue mitigates the progression of heart failure and can reverse cardiac remodeling. Recent publications have sought to study the combined use of these agents, and while the results are promising, they do warrant further research. This review aims to consider these therapies separately as well as in combination.

中文翻译：

---

神经调节蛋白和干细胞在治疗心肌梗塞后的作用。

冠状动脉疾病，包括心肌梗塞 (MI)，是美国发病率和死亡率的主要原因。由于心脏组织的自我更新能力有限，MI 可导致进行性心脏病，对健康和生活质量产生持久影响。心脏干细胞的最新发现激发了对它们对患有心血管疾病的患者的潜在治疗应用的研究。研究表明，干细胞具有在体外生成心脏组织和在动物模型中帮助体内心血管功能恢复的能力。然而，干细胞作为再生疗法的长期疗效仍然未知。替代疗法的探索正在进行中，包括使用心脏生长因子神经调节蛋白-1 (NRG-1)。研究表明 NRG-1 不仅对心肌细胞 (CM) 有直接影响，而且在支持 CM 的组织内也起作用。将 NRG-1 移植到缺血心脏组织中可以减缓心力衰竭的进展，并可以逆转心脏重塑。最近的出版物试图研究这些药物的联合使用，虽然结果很有希望，但确实值得进一步研究。本综述旨在分别和联合考虑这些疗法。它们确实值得进一步研究。本综述旨在分别和联合考虑这些疗法。它们确实值得进一步研究。本综述旨在分别和联合考虑这些疗法。